PDLIM5mRNA expression level incontrol subjects and patientsat 0, 4, and8 weeks after olanzapinetreatment. The mean PDLIM5 mRNA expression level was significantly lower in naïve patients than in control subjects (naïve patients: 0.31±0.245; controls: 1.42±1.42; Wilcoxon rank sum test: *p=0.002). After 4 weeks of treatment, no significant changes were detected in PDLIM5 mRNA expression when compared with the mean mRNA level in treatment-naïve patients (after 4 weeks of treatment: 0.36±0.195; Wilcoxon rank sum test: p=0.826). The PDLIM5 mRNA expression level after 8 weeks was 0.36±0.244, with no statistical difference when compared with the mRNA level after 4 weeks of treatment (Wilcoxon rank sum test: p=0.937). The mean PDLIM5 mRNA expression level in controls and patients before and after treatment is indicated by horizontal lines.
Zain et al. BMC Medical Genetics 2012 13:91 doi:10.1186/1471-2350-13-91